LLY Research Update — June 20, 2026
Updated Thesis
Eli Lilly and Company is a leading healthcare firm specializing in drug manufacturing with a strong competitive moat in GLP-1 diabetes and obesity treatments as well as biologics manufacturing. The company is led by experienced internal management with a proven capital allocation track record. Its revenue growth is exceptionally strong, driven by its cardiometabolic franchise which accounted for over half of 2025 sales and is growing at over 40-50% annually in the most recent quarter.
The investment grade as of this refresh is B — solid business quality. High-tier business, B-tier valuation
Key Metrics at a Glance
- Revenue growth: +55.5% year over year
- Net margin: 35.0%
- Forward P/E: 38.9x
- Fair value upside: +16.7% to our estimate of $1281
Current price: $1098.13
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Eli Lilly and Company remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full LLY research →](/stocks/LLY)